IP Library Granted Patent US 10,555,961
Granted Patent B2
US 10,555,961 · App. 15/579,487 · Granted Feb 11, 2020

Materials and methods for treating bacterial infections using C-1 gentamicin

Inventors: Bruce A. Molitoris (Indianapolis, IN); Mark C. Wagner (Indianapolis, IN); Ruben M. Sandoval (Indianapolis, IN); Mark Gerard Goebl (Indianapolis, IN)
Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION; UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
A61K31/7036A61K31/351A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,555,961
App. No.
15/579,487
Granted
Feb 11, 2020
Kind
B2
Abstract

Various aspects relate to the use of C-1 gentamicin as an antibiotic effective for the treatment of a bacterial infection, a genetic disorder, or cancer in a subject.

Claims (17)

1. A method of treating a condition in a subject comprising administering a composition comprising C-1 gentamicin or a pharmaceutically acceptable acid addition salt thereof, wherein the composition is substantially free of C-1a gentamicin, C-2 gentamicin and C-2a gentamicin, and the condition is selected from the group consisting of a bacterial infection, a monogenic genetic disease and cancer.

2. The method of claim 1 , wherein the condition is a monogenic genetic disease that is cystic fibrosis, Hurler Syndrome, Schele syndrome, Duchenne muscular dystrophy, Becker muscular dystrophy, nephrogenic diabetes insipidus, hemophilia, dystrophic epidermolysis bullosa, or Kabuki syndrome.

3. The method of claim 1 , wherein the condition is cancer and wherein the cancer cells comprise a premature stop codon in a gene encoding a cell regulatory protein.

4. The method of claim 1 , wherein the composition has a ratio of C-1a gentamicin to C-1 gentamicin of less than 1:10 (w/w).

5. The method of claim 1 , wherein the composition has a ratio of C-2a gentamicin to C-1 gentamicin of less than 1:10 (w/w).

6. The method of claim 1 , wherein the composition has a ratio of C-1 gentamicin to total gentamicin of greater than 9:10 (w/w).

7. The method of claim 1 , wherein the composition is a liquid, and the composition comprises C-1 gentamicin at a concentration between about 1 mg/mL and about 115 mg/mL.

8. The method of claim 1 , wherein the composition is a liquid, and the composition comprises less than 1000 ppm C-1a gentamicin.

9. The method of claim 1 , wherein the composition is a liquid, and the composition comprises less than 1000 ppm C-2a gentamicin.

10. The method of claim 1 , wherein the composition is a liquid, and the composition is for intravenous or intramuscular injection.

11. The method of claim 10 , wherein the composition comprises greater than about 1 mg/kg total gentamicin.

12. The method of claim 1 , wherein the composition further comprises at least one additional antibiotic.

13. The method of claim 1 , wherein the composition comprises C-1 gentamicin or a pharmaceutically acceptable acid addition salt thereof in a therapeutically effective amount.

14. The method of claim 1 , wherein the condition is a bacterial infection.

15. A composition comprising C-1 gentamicin or a pharmaceutically acceptable acid addition salt thereof, a preservative, and a chelating agent, wherein the composition is a liquid, and the composition is substantially free of C-1 a gentamicin, C-2 gentamicin and C-2a gentamicin.

16. The composition of claim 15 , wherein the composition comprises less than 1000 ppm C-1a gentamicin.

17. The composition of claim 15 , wherein the composition comprises less than 1000 ppm C-2a gentamicin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION; UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 047948/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2017
From: MOLITORIS, BRUCE; WAGNER, MARK C; SANDOVAL, RUBEN M, JR; GOEBL, MARK GERARD
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 044290/0906 →
Continuity (2)
Provisional Application 62171762 · Jun 5, 2015
Related Publication 20180147229A1 · May 31, 2018